Multitarget CFTR Modulators Endowed with Multiple Beneficial Side Effects for Cystic Fibrosis Patients : Toward a Simplified Therapeutic Approach †
Cystic fibrosis (CF) is a multiorgan disease caused by mutations of the cystic fibrosis transmembrane conductance regulator (CFTR). In addition to respiratory impairment due to mucus accumulation, viruses and bacteria trigger acute pulmonary exacerbations, accelerating disease progression and mortality rate. Treatment complexity increases with patients' age, and simplifying the therapeutic regimen represents one of the key priorities in CF. We have recently reported the discovery of multitarget compounds able to "kill two birds with one stone" by targeting F508del-CFTR and PI4KIIIβ and thus acting simultaneously as CFTR correctors and broad-spectrum enterovirus (EV) inhibitors. Starting from these preliminary results, we report herein a hit-to-lead optimization and multidimensional structure-activity relationship (SAR) study that led to compound 23a. This compound showed good antiviral and F508del-CFTR correction potency, additivity/synergy with lumacaftor, and a promising in vitro absorption, distribution, metabolism, and excretion (ADME) profile. It was well tolerated in vivo with no sign of acute toxicity and histological alterations in key biodistribution organs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:62 |
|---|---|
| Enthalten in: |
Journal of medicinal chemistry - 62(2019), 23 vom: 12. Dez., Seite 10833-10847 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tassini, Sabrina [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 22.06.2020 Date Revised 22.06.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1021/acs.jmedchem.9b01416 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM303331305 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM303331305 | ||
| 003 | DE-627 | ||
| 005 | 20231225112613.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1021/acs.jmedchem.9b01416 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1011.xml |
| 035 | |a (DE-627)NLM303331305 | ||
| 035 | |a (NLM)31729878 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tassini, Sabrina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Multitarget CFTR Modulators Endowed with Multiple Beneficial Side Effects for Cystic Fibrosis Patients |b Toward a Simplified Therapeutic Approach † |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.06.2020 | ||
| 500 | |a Date Revised 22.06.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Cystic fibrosis (CF) is a multiorgan disease caused by mutations of the cystic fibrosis transmembrane conductance regulator (CFTR). In addition to respiratory impairment due to mucus accumulation, viruses and bacteria trigger acute pulmonary exacerbations, accelerating disease progression and mortality rate. Treatment complexity increases with patients' age, and simplifying the therapeutic regimen represents one of the key priorities in CF. We have recently reported the discovery of multitarget compounds able to "kill two birds with one stone" by targeting F508del-CFTR and PI4KIIIβ and thus acting simultaneously as CFTR correctors and broad-spectrum enterovirus (EV) inhibitors. Starting from these preliminary results, we report herein a hit-to-lead optimization and multidimensional structure-activity relationship (SAR) study that led to compound 23a. This compound showed good antiviral and F508del-CFTR correction potency, additivity/synergy with lumacaftor, and a promising in vitro absorption, distribution, metabolism, and excretion (ADME) profile. It was well tolerated in vivo with no sign of acute toxicity and histological alterations in key biodistribution organs | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a CFTR protein, human |2 NLM | |
| 650 | 7 | |a Membranes, Artificial |2 NLM | |
| 650 | 7 | |a Cystic Fibrosis Transmembrane Conductance Regulator |2 NLM | |
| 650 | 7 | |a 126880-72-6 |2 NLM | |
| 650 | 7 | |a Serum Albumin, Human |2 NLM | |
| 650 | 7 | |a ZIF514RVZR |2 NLM | |
| 700 | 1 | |a Langron, Emily |e verfasserin |4 aut | |
| 700 | 1 | |a Delang, Leen |e verfasserin |4 aut | |
| 700 | 1 | |a Mirabelli, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Lanko, Kristina |e verfasserin |4 aut | |
| 700 | 1 | |a Crespan, Emmanuele |e verfasserin |4 aut | |
| 700 | 1 | |a Kissova, Miroslava |e verfasserin |4 aut | |
| 700 | 1 | |a Tagliavini, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Fontò, Greta |e verfasserin |4 aut | |
| 700 | 1 | |a Bertoni, Simona |e verfasserin |4 aut | |
| 700 | 1 | |a Palese, Simone |e verfasserin |4 aut | |
| 700 | 1 | |a Giorgio, Carmine |e verfasserin |4 aut | |
| 700 | 1 | |a Ravanetti, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Ragionieri, Luisa |e verfasserin |4 aut | |
| 700 | 1 | |a Zamperini, Claudio |e verfasserin |4 aut | |
| 700 | 1 | |a Mancini, Arianna |e verfasserin |4 aut | |
| 700 | 1 | |a Dreassi, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Maga, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Vergani, Paola |e verfasserin |4 aut | |
| 700 | 1 | |a Neyts, Johan |e verfasserin |4 aut | |
| 700 | 1 | |a Radi, Marco |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of medicinal chemistry |d 1963 |g 62(2019), 23 vom: 12. Dez., Seite 10833-10847 |w (DE-627)NLM000006602 |x 1520-4804 |7 nnns |
| 773 | 1 | 8 | |g volume:62 |g year:2019 |g number:23 |g day:12 |g month:12 |g pages:10833-10847 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1021/acs.jmedchem.9b01416 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 62 |j 2019 |e 23 |b 12 |c 12 |h 10833-10847 | ||